The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis.

IF 2.8 4区医学 Q2 ONCOLOGY Current oncology Pub Date : 2024-11-03 DOI:10.3390/curroncol31110508

Natale Quartuccio, Vincenzo Militano, Marco Pappalardo, Luca Filippi, Oreste Bagni, Antonino Maria Moreci, Salvatore Ialuna

{"title":"The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis.","authors":"Natale Quartuccio, Vincenzo Militano, Marco Pappalardo, Luca Filippi, Oreste Bagni, Antonino Maria Moreci, Salvatore Ialuna","doi":"10.3390/curroncol31110508","DOIUrl":null,"url":null,"abstract":"Aim: To meta-analyze the utility of transarterial radioembolization (TARE) in patients with liver metastatic breast cancer (BC), based on the objective response rate (ORR) and disease control rate (DCR).Methods: A literature search was performed retrieving studies with (1) at least 10 patients with liver metastatic BC treated with TARE and (2) adequate information to derive ORR and DCR. The ORR is the ratio between patients with liver lesions showing complete response (CR) or partial response (PR) over the total number of patients treated with TARE; the DCR is the ratio between patients with CR, PR, or stable disease (SD) over the total number of patients treated with TARE.Results: Eighteen studies (650 patients) were eligible; the ORR of TARE resulted 50.71% (95% C.I.: 40.04-61.36) and the DCR resulted 88.37% (95% C.I.: 81.89-93.57). Taking into account resin spheres (395 patients), the ORR was 60.35% (95% C.I.: 46.55-73.36) and the DCR was 92.73% (95% C.I.: 87.17-96.80%). Considering glass spheres (144 patients), the ORR was 32.38% (95% C.I.: 18.43-48.16) and the DCR was 82.69% (95% C.I.: 59.29-97.26).Conclusions: This meta-analysis favors the use of TARE in patients with liver metastatic BC either with resin or glass spheres.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 11","pages":"6879-6890"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592458/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31110508","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To meta-analyze the utility of transarterial radioembolization (TARE) in patients with liver metastatic breast cancer (BC), based on the objective response rate (ORR) and disease control rate (DCR).

Methods: A literature search was performed retrieving studies with (1) at least 10 patients with liver metastatic BC treated with TARE and (2) adequate information to derive ORR and DCR. The ORR is the ratio between patients with liver lesions showing complete response (CR) or partial response (PR) over the total number of patients treated with TARE; the DCR is the ratio between patients with CR, PR, or stable disease (SD) over the total number of patients treated with TARE.

Results: Eighteen studies (650 patients) were eligible; the ORR of TARE resulted 50.71% (95% C.I.: 40.04-61.36) and the DCR resulted 88.37% (95% C.I.: 81.89-93.57). Taking into account resin spheres (395 patients), the ORR was 60.35% (95% C.I.: 46.55-73.36) and the DCR was 92.73% (95% C.I.: 87.17-96.80%). Considering glass spheres (144 patients), the ORR was 32.38% (95% C.I.: 18.43-48.16) and the DCR was 82.69% (95% C.I.: 59.29-97.26).

Conclusions: This meta-analysis favors the use of TARE in patients with liver metastatic BC either with resin or glass spheres.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

接受经动脉放射栓塞术的肝转移性乳腺癌患者的客观反应率和疾病控制率：一项 Meta 分析。

目的：根据客观反应率（ORR）和疾病控制率（DCR），荟萃分析经动脉放射栓塞术（TARE）在肝转移性乳腺癌（BC）患者中的应用：方法：进行文献检索，检索具有以下条件的研究：（1）至少有 10 名接受 TARE 治疗的肝转移性 BC 患者；（2）有足够的信息得出 ORR 和 DCR。ORR是肝脏病变出现完全反应（CR）或部分反应（PR）的患者与接受TARE治疗的患者总数之比；DCR是出现CR、PR或疾病稳定（SD）的患者与接受TARE治疗的患者总数之比：18项研究（650名患者）符合条件；TARE的ORR为50.71%（95% C.I.：40.04-61.36），DCR为88.37%（95% C.I.：81.89-93.57）。考虑到树脂球（395 名患者），ORR 为 60.35%（95% C.I.：46.55-73.36），DCR 为 92.73%（95% C.I.：87.17-96.80%）。玻璃球（144 例患者）的 ORR 为 32.38%（95% C.I.：18.43-48.16），DCR 为 82.69%（95% C.I.：59.29-97.26）：这项荟萃分析支持对肝转移性 BC 患者使用树脂或玻璃球进行 TARE 治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current oncology ONCOLOGY-

CiteScore

3.30

自引率

7.70%

发文量

664

审稿时长

1 months

期刊介绍： Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.